Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -1.96% | -14.53% | -23.08% |
Mar. 26 | Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 19 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 5M | Capitalization | 7.44M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -15M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-1.59
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.94% |
1 day | -1.96% | ||
1 week | -14.53% | ||
Current month | -31.03% | ||
1 month | +19.05% | ||
3 months | -23.22% | ||
6 months | -56.71% | ||
Current year | -23.08% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Tucker
CEO | Chief Executive Officer | 55 | 21-09-15 |
Kevin Coveney
DFI | Director of Finance/CFO | 60 | 23-03-12 |
Lynn Gallant
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Webb
CHM | Chairman | 66 | 22-06-12 |
Douglas D. Lind
BRD | Director/Board Member | 64 | 21-03-16 |
Joseph Tucker
CEO | Chief Executive Officer | 55 | 21-09-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1 | -1.96% | 266,692 |
24-03-27 | 1.02 | -3.77% | 389,193 |
24-03-26 | 1.06 | +0.95% | 306,184 |
24-03-25 | 1.05 | -7.08% | 445,030 |
24-03-22 | 1.13 | -3.42% | 298,506 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.08% | 5.51M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |